Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Genzyme is all set to market and sell Campath MabCampath (alemtuzumab), Fludara (fludarabine) and Leukine (sargramostim), globally.
Subscribe to our email newsletter
Bayer HealthCare and Genzyme have received regulatory approvals for the strategic alliance announced on March 31, 2009. With the approval, the legal closing of the transaction is now completed.
Under this agreement, Bayer licenses its hematological oncology products to Genzyme along with the transfer of its current commercial portfolio to Genzyme.
Moreover, Genzyme will begin to market and sell Campath MabCampath (alemtuzumab), Fludara (fludarabine) and Leukine (sargramostim) globally.
Genzyme will be responsible for developing, marketing and selling the acquired oncology products, and will record sales revenue in the US and more than 90 other countries.
During a transition period following closing, Genzyme has contracted with Bayer to provide continuing services in certain countries to ensure uninterrupted product supply to patients or support services to providers.
Gunnar Riemann, Member of Executive Committee at Bayer HealthCare, said: “This transaction provides greater long-term profitability for two of our most important franchises – MS and Oncology, and affirms our strong commitment to better serve patients and physicians in the MS community,”